Login to Your Account



KalVista Launches with $13.1M To Back DME Treatment R&D

By Nuala Moran


Tuesday, August 23, 2011
LONDON – Vantia Therapeutics Ltd. has raised £8 million (US$13.1 million) for the development of a portfolio of plasma kallikrein inhibitors it is spinning out into a new company co-founded with diabetes experts at Harvard Medical School.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription